{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:31Z","timestamp":1792788271064,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["R01DA052580"],"award-info":[{"award-number":["R01DA052580"]}]},{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["R01DA052580"],"award-info":[{"award-number":["R01DA052580"]}]},{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["R01DA052580"],"award-info":[{"award-number":["R01DA052580"]}]},{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["R01DA052580"],"award-info":[{"award-number":["R01DA052580"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01097-5","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T06:02:44Z","timestamp":1728885764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Xylazine awareness and attitudes among people who use drugs in Ohio, 2023\u20132024"],"prefix":"10.1186","volume":"21","author":[{"given":"Nichole L.","family":"Michaels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Bista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Short Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"1097_CR1","unstructured":"United State Drug Enforcement Administration [internet]. Statement from DEA Administrator Anne Milgram on the Increase in DEA Fentanyl Seizures Containing Xylazine. https:\/\/www.dea.gov\/documents\/2024\/2024-04\/2024-04-26\/statement-dea-administrator-anne-milgram-increase-dea-fentanyl. Accessed 12 June 2024."},{"key":"1097_CR2","unstructured":"National Institute on Drug Abuse, National Institutes of Health [internet]. Xylazine. https:\/\/nida.nih.gov\/research-topics\/xylazine#references. Accessed 12 June 2024."},{"key":"1097_CR3","first-page":"503","volume":"71","author":"N Chhabra","year":"2022","unstructured":"Chhabra N, Mir M, Hua MJ, Berg S, Nowinski-Konchak J, Aks S, Arunkumar P. Xylazine related deaths \u2013 Cook County Illinois, 2017\u20132021. MMWR. 2022;71:503\u20134.","journal-title":"MMWR"},{"key":"1097_CR4","doi-asserted-by":"publisher","unstructured":"Korn WR, Stone MD, Haviland KL, Toohey JM, Stickle DF. High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021. Clin Chim Acta. 2021;521:151\u2013154. https:\/\/doi.org\/10.1016\/j.cca.2021.07.010. Epub 2021 Jul 12. PMID: 34265257.","DOI":"10.1016\/j.cca.2021.07.010"},{"issue":"7","key":"1097_CR5","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","volume":"240","author":"S Choi","year":"2023","unstructured":"Choi S, Irwin MR, Kiyatkin EA. Xylazine effects on opioid-induced brain hypoxia. Psychopharmacology. 2023;240(7):1561\u201371. https:\/\/doi.org\/10.1007\/s00213-023-06390-y. Epub 2023 Jun 21. PMID: 37340247.","journal-title":"Psychopharmacology"},{"key":"1097_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","volume":"240","author":"K Ruiz-Col\u00f3n","year":"2014","unstructured":"Ruiz-Col\u00f3n K, Chavez-Arias C, D\u00edaz-Alcal\u00e1 JE, et al. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1\u20138.","journal-title":"Forensic Sci Int"},{"key":"1097_CR7","doi-asserted-by":"publisher","unstructured":"Smith MA, Biancorosso SL, Camp JD, Hailu SH, Johansen AN, Morris MH, Carlson HN. Tranq-Dope Overdose and Mortality: Lethality Induced by Fentanyl and Xylazine. bioRxiv [Preprint]. 2023 Sep 26:2023.09.25.559379. https:\/\/doi.org\/10.1101\/2023.09.25.559379. PMID: 37808678; PMCID: PMC10557575.","DOI":"10.1101\/2023.09.25.559379"},{"issue":"1","key":"1097_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/15563650.2024.2309326","volume":"62","author":"HL Hays","year":"2024","unstructured":"Hays HL, Spiller HA, DeRienz RT, Rine NI, Guo HT, Seidenfeld M, Michaels NL, Smith GA. Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities. Clin Toxicol (Phila). 2024;62(1):26\u201331. Epub 2024 Feb 14. PMID: 38353935.","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"1097_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/15563650.2022.2159427","volume":"61","author":"JS Love","year":"2023","unstructured":"Love JS, Levine M, Aldy K, Brent J, Krotulski AJ, Logan BK, Vargas-Torres C, Walton SE, Amaducci A, Calello D, Hendrickson R, Hughes A, Kurt A, Judge B, Pizon A, Schwarz E, Shulman J, Wiegan T, Wax P, Manini AF. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol (Phila). 2023;61(3):173\u201380. PMID: 37014353; PMCID: PMC10074294.","journal-title":"Clin Toxicol (Phila)"},{"key":"1097_CR10","doi-asserted-by":"publisher","first-page":"102151","DOI":"10.1016\/j.jflm.2021.102151","volume":"79","author":"MG Garc\u00eda","year":"2021","unstructured":"Garc\u00eda MG, P\u00e9rez-C\u00e1rceles MD, Osuna E, Legaz I. Drug-facilitated sexual assault and other crimes: a systematic review by countries. J Forensic Leg Med. 2021;79:102151. https:\/\/doi.org\/10.1016\/j.jflm.2021.102151.","journal-title":"J Forensic Leg Med"},{"key":"1097_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jdcr.2023.04.016","volume":"36","author":"J Wei","year":"2023","unstructured":"Wei J, Wachuku C, Berk-Krauss J, Steele KT, Rosenbach M, Messenger E. Severe cutaneous ulcerations secondary to xylazine (tranq): a case series. JAAD Case Rep. 2023;36:89\u201391. https:\/\/doi.org\/10.1016\/j.jdcr.2023.04.016. PMID: 37274146; PMCID: PMC102324.","journal-title":"JAAD Case Rep"},{"key":"1097_CR12","unstructured":"United States Drug Enforcement Administration. Public Safety Alert. DEA reports widespread threat of fentanyl mixed with xylazine. https:\/\/www.dea.gov\/alert\/dea-reports-widespread-threat-fentanyl-mixed-xylazine. Accessed 18 September 2024."},{"key":"1097_CR13","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7226a4","author":"M Kariisa","year":"2023","unstructured":"Kariisa M, O\u2019Donnell J, Kumar S, Mattson CL, Goldberger BA. MMWR Morb Mortal Wkly Rep. 2023;72(26):721\u20137. https:\/\/doi.org\/10.15585\/mmwr.mm7226a4. PMID: 37384558; PMCID: PMC10328484. Illicitly Manufactured Fentanyl-Involved Overdose Deaths with Detected Xylazine - United States, January 2019-June 2022."},{"key":"1097_CR14","doi-asserted-by":"publisher","unstructured":"Spencer MR, Cisewski JA, Warner M, Garnett MF. Drug overdose deaths involving xylazine: United States, 2018\u20132021. Vital Statistics Rapid Release; no 30. Hyattsville, MD: National Center for Health Statistics. 2023. https:\/\/doi.org\/10.15620\/cdc:129519","DOI":"10.15620\/cdc:129519"},{"key":"1097_CR15","doi-asserted-by":"publisher","first-page":"104154","DOI":"10.1016\/j.drugpo.2023.104154","volume":"120","author":"T Quijano","year":"2023","unstructured":"Quijano T, Crowell J, Eggert K, Clark K, Alexander M, Grau L, Heimer R. Xylazine in the drug supply: emerging threats and lessons learned in areas with high levels of adulteration. Int J Drug Policy. 2023;120:104154. https:\/\/doi.org\/10.1016\/j.drugpo.2023.104154.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1097_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, Stahl NE, Hill LG, McElligott Z, Dasgupta N. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141. https:\/\/doi.org\/10.1186\/s12954-023-00879-7.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1097_CR17","doi-asserted-by":"publisher","first-page":"e2350630","DOI":"10.1001\/jamanetworkopen.2023.50630","volume":"7","author":"M Cano","year":"2024","unstructured":"Cano M, Daniulaityte R, Marsiglia F. Xylazine in overdose deaths and forensic drug reports in US States, 2019\u20132022. JAMA Netw Open. 2024;7(1):e2350630. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50630. PMID: 38180756; PMCID: PMC10770774.","journal-title":"JAMA Netw Open"},{"key":"1097_CR18","unstructured":"Cauchon D. Harm Reduction Ohio [internet]. Xylazine in Ohio: \u2018It\u2019s a fentanyl thing. https:\/\/www.harmreductionohio.org\/new-report-xylazine-plentiful-in-fentanyl-but-not-in-other-drugs\/#:~:text=Because%20xylazine%20data%20prior%20to,how%20quickly%20its%20presence%20expanded.&text=Of%20all%2013%2C219%20drugs%20subject,3%2C563%20(27.0%25)%20contained%20fentanyl. Accessed 12 June 2024."},{"issue":"1","key":"1097_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1186\/s13063-024-08440-y","volume":"25","author":"A Short Mejia","year":"2024","unstructured":"Short Mejia A, Smith GA, Fernandez S, Freisthler B, Grella C, Michaels NL. Evaluating fentanyl test strips as a harm reduction strategy in rural and urban counties: study protocol for a randomized controlled trial. Trials. 2024;25(1):587. https:\/\/doi.org\/10.1186\/s13063-024-08440-y. PMID: 39232778; PMCID: PMC11373481.","journal-title":"Trials"},{"key":"1097_CR20","unstructured":"U.S. Department of Health and Human Services, Health Resources & Services Administration (HRSA). List of Rural Counties and Designated Eligible Census Tracts in Metropolitan Counties. Updated December 31. 2018. https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/rural-health\/resources\/forhp-eligible-areas.pdf. Accessed 17 September 2024."},{"issue":"1","key":"1097_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12874-018-0519-5","volume":"18","author":"W Chen","year":"2018","unstructured":"Chen W, Qian L, Shi J, Franklin M. Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification. BMC Med Res Methodol. 2018;18(1):63. https:\/\/doi.org\/10.1186\/s12874-018-0519-5.","journal-title":"BMC Med Res Methodol"},{"key":"1097_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2288-3-21","volume":"3","author":"AJ Barros","year":"2003","unstructured":"Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21. https:\/\/doi.org\/10.1186\/1471-2288-3-21.","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"1097_CR23","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","volume":"159","author":"G Zou","year":"2004","unstructured":"Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702\u20136. https:\/\/doi.org\/10.1093\/aje\/kwh090.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"1097_CR24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/oxfordjournals.aje.a114593","volume":"125","author":"S Greenland","year":"1987","unstructured":"Greenland S. Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidemiol. 1987;125(5):761\u201368. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114593.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1097_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/ADM.0000000000001264","volume":"18","author":"M Tan","year":"2024","unstructured":"Tan M, Nassau T, Kuncio D, et al. Xylazine use among people who inject drugs, Philadelphia 2022. J Addict Med. 2024;18(2):194\u2013200. https:\/\/doi.org\/10.1097\/ADM.0000000000001264.","journal-title":"J Addict Med"},{"issue":"6","key":"1097_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/ADM.0000000000001216","volume":"17","author":"A Spadaro","year":"2023","unstructured":"Spadaro A, O\u2019Connor K, Lakamana S, et al. Self-reported xylazine experiences: a mixed-methods study of Reddit subscribers. J Addict Med. 2023;17(6):691\u20134. https:\/\/doi.org\/10.1097\/ADM.0000000000001216.","journal-title":"J Addict Med"},{"issue":"1","key":"1097_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/paf.0000000000000622","volume":"42","author":"J Nunez","year":"2021","unstructured":"Nunez J, DeJoseph ME, Gill JR. Xylazine, a Veterinary Tranquilizer, detected in 42 accidental fentanyl intoxication deaths. Am J Forensic Med Pathol. 2021;42(1):9\u201311. https:\/\/doi.org\/10.1097\/paf.0000000000000622.","journal-title":"Am J Forensic Med Pathol"},{"key":"1097_CR28","unstructured":"Sacco LN, Sheikh HZ. Xylazine: Considerations for federal control. Congressional Research Service. Updated August 1, 2023. https:\/\/crsreports.congress.gov\/product\/pdf\/IN\/IN12086#:~:text=Xylazine%20is%20not%20currently%20controlled,DEA%20to%20regulate%20the%20substance. Accessed 18 September 2024."},{"key":"1097_CR29","unstructured":"Lampe JR. Xylazine and the Controlled Substances Act: Legal considerations for Congress. Congressional Research Service. July 19, 2024. https:\/\/crsreports.congress.gov\/product\/pdf\/LSB\/LSB11202#:~:text=on%20drug%20paraphernalia.-,Considerations%20for%20Congress,%2C%20zoo%20animals%2C%20and%20livestock. Accessed 18 September 2024."},{"key":"1097_CR30","unstructured":"State of Ohio Office of the Governor. Governor DeWine Authorizes Emergency Classification of Xylazine as Schedule III Controlled Substance. https:\/\/governor.ohio.gov\/media\/news-and-media\/Governor-DeWine-Authorizes-Emergency-Classification-of-Xylazine-as-Schedule-III-Controlled-Substance. Accessed 17 September 2024."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01097-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T17:02:34Z","timestamp":1728925354000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01097-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01097-5","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Nationwide Children\u2019s Hospital Institutional Review Board has given ethical approval for this study (STUDY00001919). Informed consent was obtained from all study participants according to our IRB-approved study protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}